Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy
Open Access
- 1 September 2007
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 120 (3) , 602-609
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- A Hybrid Expressing Genetically Engineered Major Allergens of the Parietaria Pollen as a Tool for Specific Allergy VaccinationInternational Archives of Allergy and Immunology, 2006
- A sensitive monoclonal antibody‐based enzyme‐linked immunosorbent assay to quantify Parietaria judaica major allergens, Par j 1 and Par j 2Clinical & Experimental Allergy, 2005
- Allergen-specific immunotherapy with recombinant grass pollen allergensJournal of Allergy and Clinical Immunology, 2005
- Can we genetically engineer safer and more effective immunotherapy reagents?Current Opinion in Allergy and Clinical Immunology, 2003
- Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicityThe FASEB Journal, 2002
- Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1The FASEB Journal, 2001
- Mechanisms of allergen‐specific immunotherapyAllergy, 2000
- Parietaria pollen allergensAllergy, 1998
- cDNA cloning, sequence analysis and allergological characterization of Par j 2.0101, a new major allergen of the Parietaria judaica pollenFEBS Letters, 1996
- cDNA cloning, expression and primary structure of Par j I, a major allergen of Parietaria judaica pollenFEBS Letters, 1994